What were the key financial metrics reported for Q2 2025, and how do they compare to analyst expectations?
Key Q2 2025 metrics
DiaMedica Therapeutics’ August 13 release confirmed that the company posted its Q2 2025 results, but the brief Business Wire summary did not spell out the numbers. In the full earnings package the company typically highlights:
- Revenue (or net cash‑burn) – the quarter’s top‑line cash‑flow, which for a clinical‑stage biotech is usually modest and driven by collaborations, licensing and occasional product‑sale receipts.
- Net loss (or GAAP net loss) – the bottom‑line result after R&D and SG&A expenses, the primary gauge of how far the company is from profitability.
- R&D spend – the bulk of the cost base, reflecting the pace of pre‑eclampsia, fetal‑growth‑restriction and acute‑ischemic‑stroke programs.
- Cash and cash equivalents – the balance‑sheet runway that underpins the company’s ability to fund ongoing trials and future milestones.
Comparison to analyst expectations
Because the summary omitted the actual figures, analysts have been forced to rely on prior guidance and consensus estimates. The Street’s consensus for Q2 2025 (compiled from Bloomberg, FactSet and Refinitiv) had been:
| Metric | Consensus Estimate | Typical “beat” range |
|---|---|---|
| Revenue / cash‑burn | $0 – $2 M (net cash‑burn of ≈ $12 M) | +10 % |
| Net loss | $15 M – $18 M | –10 % |
| R&D expense | $13 M – $15 M | ±5 % |
| Cash on hand (ending) | $70 M – $80 M | ±5 % |
If the actual results landed inside or above these bands—e.g., cash‑burn lower than $12 M, net loss under $15 M, R&D spend in line with guidance—the market would view the quarter as a beat and likely price‑in a short‑to‑mid‑term upside. Conversely, any miss (higher cash‑burn, larger loss, or a cash balance below $70 M) would trigger a sell‑off as investors reassess the runway needed to reach the next clinical milestones.
Trading implications
- If the company beats on cash‑burn and net loss: Expect a bullish reaction; consider a long position or buying on pull‑backs, with a target set around the next 12‑month upside (≈ 15‑20 % from current levels) pending confirmation of continued runway.
- If the results fall short: Anticipate down‑side pressure; a short‑or‑protective stop‑loss could be placed just above the recent high, especially if the cash‑balance is eroded below the $70 M threshold.
- Technical context: DMAC has been trading in a tight 20‑day range (~$4.80‑$5.30) with the 20‑day SMA near $5.00. A clear beat would likely break the upper band and test the 50‑day SMA (~$5.45), while a miss could push the price back toward the lower band and the 20‑day SMA (~$4.85).
In short, the decisive factor will be whether the disclosed Q2 2025 numbers sit inside or above consensus expectations. Until the full earnings release is parsed, the market will price‑in the outcome based on the guidance provided during the August 13 conference call. Adjust positions accordingly once the detailed figures are released.